3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Ovarian Neoplasms
5
Endometrial Neoplasms
5
Uterine Cervical Neoplasms
2
Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Low Grade Serous Ovarian Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Granulosa Cell Ovarian Cancer
1
Fallopian Tube Neoplasms
1
Endometrial Stromal Tumors
1
Carcinoma
1
Breast Diseases
1
Interventions
pembrolizumab
18
Cyclophosphamide
9
fludarabine
8
Nivolumab
8
cemiplimab
5
Carboplatin
5
atezolizumab
4
Gemcitabine
4
Filgrastim
4
Drug Therapy
4
Docetaxel
4
Cisplatin
4
palbociclib
3
durvalumab
3
Paclitaxel
3
Interleukin-2
3
Bortezomib
3
fludarabine phosphate
2
epacadostat
2
belinostat
2
avelumab
2
amminedichloro(2-methylpyridine)platinum(II)
2
aldesleukin
2
Tobacco Use Cessation Devices
2
Temozolomide
2
SS1(dsFv)PE38
2
Riluzole
2
Peripheral Blood Stem Cell Transplantation
2
Oncolytic Virotherapy
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Anastrozole
×
Gynecologic
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled